Genitourinary (GU) Cancer
Roche is leading the investigation of new options for patients suffering from genitourinary cancer, exploring the potential of cancer immunotherapy and treatment tailored to individuals.
ASCO GU 2019
ASCO-GU_Poster_2019 Long-term outcomes in elderly patients (pts) from IMvigor210: atezolizumab (atezo) in metastatic urothelial cancer (mUC)
This poster presents results from a post-hoc analysis investigating the efficacy and safety of atezolizumab monotherapy in IMvigor210 patients with mUC ≥ 65 and ≥ 75 years. In this post hoc analysis, ORR, DOR, OS and safety were evaluated in subgroups based on age and PD-L1 status.
ASCO-GU_Poster_2019 Treatment (Tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving atezolizumab (atezo) monotherapy in US clinical practice
This poster presents the first analysis of atezolizumab monotherapy use in patients with mUC treated in routine clinical practice in the US. 1L and 2L+ treatment data from the Flatiron Health EHR-derived database were compared with data from the IMvigor210 and IMvigor211 clinical trials. Time on treatment, distribution of treatment cycles and patient characteristics by treatment are reported.
Popular From Previous Congresses
ASCO-GU 2018 oral - IMmotion151: A Randomized Phase III Study of ▼Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma
IMmotion151 is randomized Phase III study evaluating the efficacy and safety ▼atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib in patients with treatment-naive advanced or metastatic renal cell carcinoma (RCC). Coprimary endpoints were investigator-assessed progression-free survival (PFS) in PD-L1 + (≥ 1% PD-L1 expression on tumor-infiltrating immune cells) patients and overall survival (OS) in intent-to-treat (ITT) patients; secondary endpoints included PFS in ITT patients, ORR and DOR.
ASCO 2018 poster- ▼Atezolizumab (Atezo) in Special Populations: Analyses From an Expanded Access Program (EAP) in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma (mUC)
This poster presents clinical outcomes in special populations from an expanded access study of atezolizumab in platinum-treated metastatic urothelial carcinoma. Subgroups evaluated include patients with impaired baseline renal function or variant histology. The impacts of such clinical features on efficacy and safety outcomes are described. ▼Atezolizumab: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu
IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma
This presentation reports the primary efficacy and safety data for the Phase 3 IMvigor130 trial investigating ▼atezolizumab with or without chemotherapy versus placebo with chemotherapy in patients with metastatic urothelial cancer who have not been previously treated. With a median follow-up of 11.8 months, final PFS, interim OS, ORR, DOR, and safety results will be shown.
ASCO-GU 2018 poster - Atezolizumab vs Chemotherapy in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Immune Biomarkers, Tumor Mutational Burden and Clinical Outcomes From the Phase III IMvigor211 Study
The IMvigor211 study was the first randomized Phase III trial to compare ▼atezolizumab vs chemotherapy in patients with metastatic urothelial carcinoma who had previously progressed on platinum-based chemotherapy. The analysis of Immune biomarkers, tumor mutational burden and clinical outcomes suggest the utility of identifying biomarker combinations in future prospective studies.
Safety and efficacy of ▼atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
In prespecified analyses of the subgroup of 35 patients with pre-existing autoimmune disease (AID) treated with ▼atezolizumab for urinary tract carcinoma in the single-arm Phase IIIb SAUL study, incidences of adverse events (AEs) of special interest and treatment-related AEs appeared acceptable. Efficacy in patients with AID seemed at least similar to efficacy in non-AID patients. Treating patients with AID requires caution but AID is not a barrier to ▼atezolizumab therapy per se.
ASCO-GU 2018 poster - A Phase Ia Study of Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer
PCD4989g (NCT01375842) is an ongoing Phase I study of atezolizumab in patients with advanced or metastatic solid tumors and hematologic malignancies, including a cohort of patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective of this study was to evaluate the safety and tolerability of ▼atezolizumab; overall survival (OS) was an exploratory objective. Key mCRPC cohort-specific objectives included PSA response, radiographic progression per Prostate Cancer Working Group 2 (PCWG2) criteria, and soft-tissue response per RECIST v1.1 and immune-related response criteria (irRC). In patients with heavily pretreated mCRPC, ▼atezolizumab demonstrated long-term disease control.
A Phase Ib study of the safety and efficacy of ▼atezolizumab (atezo) + ▼bevacizumab (bev) + ▼cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
This poster presents safety and efficacy results from the primary analysis of a Phase Ib study of ▼atezolizumab + ▼bevacizumab + ▼cobimetinib in patients with metastatic colorectal cancer. Efficacy results by RAS mutant status are also described.
Clinical Outcomes by Sex With ▼Atezolizumab Monotherapy in Patients With Locally Advanced/Metastatic Urothelial Carcinoma
This poster presents post-hoc analyses of outcomes by sex among patients with mUC who received ▼atezolizumab. This analysis reports patient demographic and clinical characteristics, objective response rate and overall survival from four clinical trials of ▼atezolizumab (PCD4898g, IMvigor210, IMvigor211, SAUL).
ASCO-GU 2018 poster - Comparative Effectiveness of Non–Cisplatin-Based First-Line Regimens in Patients With Metastatic Urothelial Carcinoma: Veterans Affairs Control Cohorts vs IMvigor210
Many patients with metastatic urothelial cancer are ineligible for standard-of-care first-line cisplatin-based chemotherapy and receive alternatives such as carboplatin-based regimens (typically carboplatin-gemcitabine). This study compared overall survival between patients with mUC treated with 1L ▼atezolizumab from IMvigor210 and patients with mUC treated with 1L non-cisplatin carboplatin-based chemotherapy in real-world practice (Veterans Administration).